Back to search
FDAFDA · Food and drugs·Recall number D-067-2013

Pradaxa (dabigatran etexilate), 75 mg Capsules, 60 count bottles, Rx only, Distributed by Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT --- NDC 0597-0149-54

Published December 5, 2012 · Recall initiated: November 5, 2012

Summary

FDA records drug Class II recall D-067-2013, published December 5, 2012 and initiated November 5, 2012. Recalling firm: Boehringer Ingelheim Roxane Inc; Status: Terminated; Reported quantity: 8,381 bottles; Lot: Lot 201900 Expiration Date: JAN 2015. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Defective container; damaged bottles could allow moisture to get into the bottle and thus may impair the quality of the product

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Boehringer Ingelheim Roxane Inc
Distributor
Nationwide
Lot
Lot 201900 Expiration Date: JAN 2015
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Pradaxa (dabigatran etexilate), 75 mg Capsules, 60 count bottles, Rx only, Distributed by Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT --- NDC 0597-0149-54 recalled?

Yes. FDA published recall D-067-2013 on December 5, 2012. Reported hazard: Defective container; damaged bottles could allow moisture to get into the bottle and thus may impair the quality of the product

What should I do if I have this product?

Voluntary: Firm initiated · Letter